Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sintilimab by Innovent Biologics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...
Sintilimab by Innovent Biologics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According...
Sintilimab by Innovent Biologics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Sintilimab by Innovent Biologics for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According...
Sintilimab by Innovent Biologics for Colorectal Cancer: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase...
Sintilimab by Innovent Biologics for Pleomorphic Liposarcoma: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase...